1. Home
  2. URGN vs FLXS Comparison

URGN vs FLXS Comparison

Compare URGN & FLXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • URGN
  • FLXS
  • Stock Information
  • Founded
  • URGN 2004
  • FLXS 2001
  • Country
  • URGN United States
  • FLXS United States
  • Employees
  • URGN N/A
  • FLXS N/A
  • Industry
  • URGN Biotechnology: Pharmaceutical Preparations
  • FLXS Home Furnishings
  • Sector
  • URGN Health Care
  • FLXS Consumer Discretionary
  • Exchange
  • URGN Nasdaq
  • FLXS Nasdaq
  • Market Cap
  • URGN 181.2M
  • FLXS 175.4M
  • IPO Year
  • URGN 2017
  • FLXS N/A
  • Fundamental
  • Price
  • URGN $14.82
  • FLXS $35.89
  • Analyst Decision
  • URGN Strong Buy
  • FLXS
  • Analyst Count
  • URGN 9
  • FLXS 0
  • Target Price
  • URGN $26.81
  • FLXS N/A
  • AVG Volume (30 Days)
  • URGN 5.9M
  • FLXS 17.9K
  • Earning Date
  • URGN 08-12-2025
  • FLXS 08-18-2025
  • Dividend Yield
  • URGN N/A
  • FLXS 2.23%
  • EPS Growth
  • URGN N/A
  • FLXS N/A
  • EPS
  • URGN N/A
  • FLXS 2.55
  • Revenue
  • URGN $91,871,000.00
  • FLXS $437,284,000.00
  • Revenue This Year
  • URGN $36.65
  • FLXS $8.34
  • Revenue Next Year
  • URGN $88.35
  • FLXS $4.01
  • P/E Ratio
  • URGN N/A
  • FLXS $14.10
  • Revenue Growth
  • URGN 8.98
  • FLXS 7.24
  • 52 Week Low
  • URGN $3.42
  • FLXS $28.81
  • 52 Week High
  • URGN $18.15
  • FLXS $65.87
  • Technical
  • Relative Strength Index (RSI)
  • URGN 73.80
  • FLXS 65.59
  • Support Level
  • URGN $6.92
  • FLXS $29.39
  • Resistance Level
  • URGN $15.22
  • FLXS $36.87
  • Average True Range (ATR)
  • URGN 1.57
  • FLXS 1.64
  • MACD
  • URGN 1.17
  • FLXS 0.80
  • Stochastic Oscillator
  • URGN 96.49
  • FLXS 93.40

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About FLXS Flexsteel Industries Inc.

Flexsteel Industries Inc is a United States-based company that manufactures, imports, and markets residential upholstered wooden furniture products. Its product offerings include sofas, loveseats, chairs, rockers, desks, tables, convertible bedding units, and bedroom furniture. The company's products are intended for use in home, office, hotel, healthcare, and other contract applications. A featured component in the company's upholstered furniture is the durable Blue Steel Spring. It operates in the business segment of Furniture products. The company's furniture products business involves the distribution of manufactured and imported products for residential markets.

Share on Social Networks: